Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 01 entities : Beigene, ltd. save search
BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021
Published: 2021-06-01 (Crawled : 15:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.42%
H: 2.35%
C: 1.95%
presentation brukinsa leukemia phase 3 trial symposium
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Published: 2021-06-01 (Crawled : 09:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.42%
H: 2.35%
C: 1.95%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 1.79%
H: 0.03%
C: -3.56%
treatment potential dermatitis phase 3 atopic dermatitis
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.